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Laforin is a unique human dual-speciﬁcity phosphatase as it contains an amino terminal carbohydrate
binding module (CBM). Laforin gene mutations lead to Lafora disease, a progressive myoclonus epilepsy
with an early fatal issue. Previous attempts to produce recombinant laforin faced various difﬁculties,
namely the appearance of protein inclusion bodies, the contamination with bacterial proteins and a high
tendency of the protein to aggregate, despite the use of fusion tags to improve solubility and ease the
puriﬁcation process. In this work, we have expressed human laforin inEscherichia coli in the form of inclu-
sion bodies devoid of any fusion tags. After a rapid dilution refolding step, the protein was puriﬁed by two
chromatographic steps, yielding 5–7 mg of puriﬁed protein per liter of bacterial culture. The puriﬁed pro-
tein was shown to have the kinetic characteristics of a dual-speciﬁcity phosphatase, and a functional car-
bohydrate binding module.
With this protocol, we were able for the ﬁrst time, to produce and purify laforin without fusion tags in
the amounts traditionally needed for the crystallographic structural studies paving the way to the under-
standing of the molecular mechanisms of laforin activity and to the development of novel therapies for
Lafora disease.
 2010 Elsevier Inc. All rights reserved.Introduction
Laforin is a human dual-speciﬁcity protein phosphatase that
contains an N-terminal carbohydrate binding module (CBM)
domain and a C-terminal HCXXGXXR(S/T) phosphatase catalytic
active site motif [1,2]. The CBM domain encompassing the ﬁrst
120 amino acids could be aligned with starch binding domains of
family CBM20, CAZy database (http://www.cazy.org/fam/
CBM20.html), whose members are also often designated as starch
binding domains.
Laforin was found to be involved with Lafora disease, an early
onset fatal progressive myoclonus epilepsy with autosomal reces-
sive inheritance [3–6]. Clinically, the disease is characterized by
myoclonic seizures and cumulative neurological deterioration,
and the appearance of deposits of insoluble hyperphosphorylated
glucans exhibiting sparse branching, called Lafora bodies, in the
cytoplasm of nearly all cell types [3–5]. Because laforin has a
CBM, it was hypothesized that it might be involved in glycogen
metabolism. In fact it was shown that the CBM domain of laforin
targets the phosphatase domain to glycogen [2] which in turnll rights reserved.
, Biocant, Parque Tecnológico
nhede, Portugal. Fax: +351
astanheira).can dephosphorylate glycogen [7]. Mutations of laforin that disable
the glycogen binding domain also eliminate its ability to dephos-
phorylate glycogen, leading to excessive phosphorylation of glyco-
gen that was proposed to lead to the aberrant branching of
glycogen and the formation of Lafora bodies [7]. The studies that
have shown the interaction of laforin with other glycogen synthe-
sis enzymes, such as the glycogen targeting regulatory subunit R5
of protein phosphatase 1 [8,9], glycogen synthase kinase 3 [10] and
regulatory proteins such as malin, an E3 ubiquitin ligase that tar-
gets laforin for degradation [11], helped to explain the formation
of Lafora bodies and the demonstration of a crucial role for laforin
in glycogen synthesis [12].
While multiple groups have shown that laforin and other glucan
phosphatases dephosphorylate phosphoglucans, there is no struc-
ture of a glucan phosphatase and little is known about the mecha-
nism whereby they perform this action [13]. Very recently the
phosphoglucan interacting regions of laforin were determined
[13], but its three-dimensional structure remains elusive. Several
groups have attempted to express laforin, and until now only
tagged versions of the protein have been described with several
groups describing the high tendency of laforin to precipitate, the
formation of inclusion bodies (IBs) and the co-precipitation of
other proteins, mostly chaperones, even purifying the protein by
afﬁnity chromatography [14–17]. Nevertheless, the recombinant
forms of laforin have been described to hydrolyze dual-speciﬁcity
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[14–17], and to bind and be inhibited by glycogen and related
polysaccharides [16–18].
In this paper, we present a novel method to produce high
amounts of full-length laforin devoid of fusion tags. The character-
ization of the puriﬁed protein revealed that recombinant laforin is
in dimeric state and has similar kinetic and carbohydrate binding
properties to the material produced in the previously described
puriﬁcation attempts.2 Abbreviations used: pNPP, p-nitrophenyl phosphate; OMFP, 3-O-methylﬂuores-
ceinyl phosphate.Materials and methods
The plasmid pET21a(+) containing the cDNA coding for full-
length laforin with a C-terminal hexahistidine tag was a kind gift
from Dr. Jack Dixon (U. Michigan, Ann Arbour, Michigan, USA) [2].
Site-directed mutagenesis
To remove the hexahistidine tag coded by the laforin-his_pE-
T21a(+) construction we have inserted a stop codon at laforin C-
terminal by site-directed mutagenesis. For that we have designed





The mutagenesis was performed using the QuikChange Site-Di-
rected Mutagenesis Kit (Stratagene) according to manufacturer’s
instructions. The insertion of the TGA stop codon also removed
the Xho I restriction endonuclease site that was previously used
to clone the laforin cDNA [2], and this change allowed us to iden-
tify the positively mutated clones. The positive clones identiﬁed
were later conﬁrmed by automated DNA sequencing analysis.
Expression, refolding and puriﬁcation
The culture ofEscherichia coli BL21 star (Invitrogen) transformed
with the appropriate expression construct was grown in 1L LB
(Luria–Bertani) medium with 30 lg/ml ampicillin at 37 C,
185 rpm in New Brunswick Innova 44R incubator shakers. The
expression of laforin was induced by the addition of IPTG into
the culture medium at mid-log phase (OD600 = 0.6) to 0.5 mM ﬁnal
concentration. After 3 h, cells were harvested, resuspended in
50 ml of TN buffer (50 mM Tris, 150 mM NaCl (pH 7.4)) and lysed
by adding lysozyme (100 lg/ml). After freeze and thawing, deoxy-
ribonuclease I (100 lg/ml) and MgCl2 (100 mM) were added and
the extract incubated at 4 C for 1 h with occasional stirring. The
inclusion bodies were then washed for 3 h with 1 L of TN buffer
(50 mM Tris, 150 mM NaCl (pH 7.4)), pelleted at 10,000g and then
washed again for another 3 h with 1 L of TNT buffer (50 mM Tris,
50 mM NaCl (pH 7.4), 0.1% Triton X-100 (v/v)) followed by centri-
fugation at 10,000g. The pelleted inclusion bodies were then dis-
solved in 50 ml of 8 M urea buffer (8 M urea, 0.1 M Tris, 1 mM
glycine, 1 mM EDTA, pH 10.5), with 100 mM b-mercaptoethanol
and were then rapidly diluted (20-fold) at room temperature into
1 L of 20 mM Tris base, 0.5 mM oxidized/1.25 mM reduced gluta-
thione, 0.5 mM DTT without prior pH adjustment; the pH was then
slowly adjusted to 8.0 with 6 M HCl and the solution was kept at
cold room until puriﬁcation.
After 3–4 days to a week period the refolded laforin solution
was ﬁrst concentrated by tangential ﬂow ultraﬁltration (Sartocon
Slice – Sartorius) to approximately 150 ml, followed by a N2
pressurized stirred cell concentrator (Amicon 8200 – Millipore)to 12–15 ml. After ultracentrifugation to clarify the solution
(100,000g, 20 min, 4 C), the protein was applied to a 320–330 ml
bed volume HiLoad 26/60 Superdex 200 prep grade column (Amer-
sham) pre-equilibrated at room temperature with 20 mM Tris,
0.4 M urea, pH 8.0 at 2.0 ml/min. The collected fractions with phos-
phatase activity were pooled and applied to a Mono Q HR 5/5
(Amersham) column equilibrated with 20 mM Tris, 0.4 M urea,
pH 8.0 at 0.75 ml/min. The elution was done by a linear NaCl gra-
dient from 0 to 0.5 M.
SDS–PAGE
The protein purity was assessed by SDS/PAGE using 12.5% gels
in a BioRad Mini Protean III electrophoresis apparatus according
to the method of Laemmli, and stained with Coomassie brilliant
blue R-250.
Enzyme assays and kinetics
During puriﬁcation the enzyme activity was monitored using
pNPP2 at a standard concentration of 10 mM at 30 C, in 1 ml (total
volume) of 50 mM Tris/HCl buffer, pH 7.2, with a Varian Cary 100
UV/vis Spectrophotometer, following the increase of OD410 induced
by the release of p-nitrophenol (with e405nm = 18.3 mM1 cm1)
[16]. For kinetic parameter determination the concentration of
pNPP varied, while the buffer and temperature conditions were
the same. The kinetic parameters determination was also per-
formed using OMFP as substrate under the same conditions used
for pNPP. These studies were performed by ﬂuorescence analysis
using an Horiba Jobin Yvon Fluoromax-3 ﬂuorometer following
the ﬂuorescence emission of the product formed with excitation
wavelength set at 485 nm and emission wavelength at 530 nm.
Since OMFP was dissolved in DMSO, the activity assays using OMFP
were done in the presence of 10% DMSO. For determination of the
relation between ﬂuorescence units and product concentration,
5 nmol OMFP were hydrolyzed to completion and the ﬂuorescence
difference between the non-hydrolyzed substrate and the com-
pletely hydrolyzed product were measured.
Protein was quantiﬁed by the BCA (Bicinchoninic Acid) Protein
Assay (Pierce – Thermo Scientiﬁc), using bovine serum albumin as
protein standard, according to manufacturer’s instructions.
The data were ﬁtted to the Michaelis–Menten equation (Eq. 1)
using the software Enzyme Kinetics Module – Sigmaplot (Systat
Software Inc.).
V ¼ kcat½S=ðKM þ ½SÞ ð1Þ
Testing the effect of glycogen on laforin activity was carried out
with 20 nM laforin in the presence of 20 lM OMFP in the same
conditions described before.
Recombinant protein analysis
Analytical size exclusion chromatography was performed in
AKTA FPLC system (GE/Amersham) using a Superose 12 10/300
GL (GE/Amersham). Laforin (250 ll) were applied to the column
pre-equilibrated with 20 mM Tris, 0.4 M urea, 150 mM NaCl, pH
8.0 at 0.4 ml/min at room temperature. Column calibration was
performed under the manufacturer’s instructions using the low
molecular weight and the high molecular weight gel ﬁltration cal-
ibration kits (GE/Amersham). The protein size was also determined
by dynamic light scattering (DLS; Malvern Instruments – Nano
Zetasizer ZS with software version 6.01), allowing an estimation
Table 1
















Refoldeda 7 7250 39 186 100
Superdex 38 5524 22 251 76 1.3
Mono Q 6.5 3400 7 486 47 2.6
a The starting material was 1 L culture of E. coli expressing laforin (weight of wet
bacteria: 4.2 g; total protein in bacterial extract: 336 mg; weight of wet inclusion
bodies: 0.61 g; total protein refolded: 122 mg).
b One Unit of activity was deﬁned as the activity corresponding to the con-
sumption of 1 lM substrate (pNPP) in 1 min at 30 C.
c Yield was calculated based on recovery of activity.
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formed at room temperature, using a protein sample at 0.5 mg/ml.
Adsorption assay
To evaluate the laforin starch binding capability, adsorption as-
says using starch were carried out. The puriﬁed protein samples
(0.25 mg/ml) were mixed with 50 mg of starch previously washed
with 50 mM Tris–HCl, 50 mM NaCl, pH 7.4, 0.1% b-mercap-
toethanol buffer, pH 7.4, for 1 h, at 4 C. Then, the mixture was cen-
trifuged (13,000 rpm, 10 min, 4 C) and the supernatant was
analyzed by SDS–PAGE. The starch was washed out with buffer
(3  0.3 ml) until no protein was detected in the supernatant.
The recombinant laforin was eluted from starch with 5 mg/ml gly-
cogen solution (0.3 ml, at 4 C for 1 h).Results and discussion
Protein expression and puriﬁcation
The plasmid construction coding for full-length laforin that we
received from Dr. Jack Dixon also coded for a C-terminal hexahisti-
dine tag [2], which had been previously associated with problems
in protein puriﬁcation and stability [15–17]. For this reason we
decided to introduce a stop codon before the hexahistidine tag cod-
ing sequence. This was accomplished by site-directed mutagenesis
using QuikChange Site-Directed Mutagenesis Kit (Stratagene).Fig. 1. Construction of laforin cDNA cloned into the expression vector pET21a(+).
The cDNA was originally cloned in between Nhe I site and the Xho I site of the
multi-cloning site in the pET21a(+) vector without stop codon. We have inserted a
stop codon at the end of laforin cDNA, resulting in the loss of Xho I site.
A B
Fig. 2. Laforin chromatographic puriﬁcation. (A) Refolding solution was concentrated dow
Tris, 0.4 M urea, pH 8.0, 2 ml/min at room temperature; (B) The fractions from the secon
Mono Q 5/50 GL equilibrated at 0.75 ml/min in 20 mM Tris, 0.4 M urea, pH 8.0. Elution wa
cells before induction; (2) E. coli cells after 3 h induction–soluble fraction; (3) cells after
(5) second peak from Superdex 200 applied to Mono Q; (6) Mono Q peak; (7) moleculaAfter the mutagenesis PCR, the positive mutant clones were iden-
tiﬁed by restriction analysis based on the loss of Xho I site and
conﬁrmed by automated DNA sequencing analysis. A diagram of
the plasmid construction is presented in Fig. 1.
After a 3-h induction with IPTG, E. coli (BL21 star) cells trans-
formedwith laforin-pET21a(+) exhibitedahigh level of recombinant
human full-length laforin expression in the insoluble fraction
(Fig. 2C, lane3). Theproteinwasﬁrst puriﬁed in the formof inclusion
bodies and after a denaturing step with 8 M urea, the refolding was
achieved using a protocol already established in our laboratory [19]
by rapid diluting the protein into a Tris–HCl solution in the presence
of reduced and oxidized forms of glutathione, DTT and 2-mercap-
toethanol, with the pH slowly adjusted to 8.0. During the refolding
step there was some protein precipitation observed by a slight
increase in solution turbidity, but the insoluble material was suc-
cessfully removedbyultracentrifugation prior to theﬁrst chromato-
graphic step. The soluble forms of the protein were applied to a
Superdex 200 gel ﬁltration column (GE Healthcare) in order to sep-
arate the soluble aggregates from the non-aggregated forms of the
protein,with thepNPPaseactivitybeingdetectedon the secondpeak
of Superdex 200 chromatogram (Fig. 2 A).
The protein was then loaded onto an anion-exchange resin in
order to obtain a more homogeneous and concentrated protein.
The results in Fig. 2 B show a major peak that proved to be the
one with highest activity (data not shown). We have also observed
some activity in the adjacent peak, but we think that this might be
due to the overlapping of the two protein peaks.
At the end of the puriﬁcation process from several expression
batches we could obtain between 5 and 7 mg of puriﬁed active
laforin per liter of expression media.
The puriﬁcation table (Table 1) shows that the starting material
after refolding was already relatively pure, since the puriﬁcation
factor was only 2.6, which is consistent with the lack of contami-
nant bands in the SDS–PAGE proﬁle of refolded protein (Fig. 2 C,C
n to 7 ml and applied to a Hiload 26/60 Superdex 200 pre-equilibrated with 20 mM
d protein peak from Superdex 200 (with phosphatase activity) were loaded onto a
s done by a gradient of NaCl; (C) SDS–PAGE analysis of protein puriﬁcation (1) E. coli
3 h induction–insoluble fraction; (4) concentrated protein applied to Superdex 200;
r weight standard. Gel was stained with Coomassie blue.
Fig. 3. Oligomerization analysis of puriﬁed laforin, by size exclusion chromatography (SEC) (A) and Dynamic Light Scattering (B). SEC – 200 ll of puriﬁed laforin were loaded
onto a Superose 12 10/300 GL equilibrated in 20 mM Tris, 0.4 M urea, 150 mM NaCl, pH 8.0 at 0.4 ml/min at room temperature that had been previously calibrated using the
GE Healthcare gel ﬁltration molecular weight calibration kits (highlighted box) The triangles indicate the elution volumes of molecular weight markers used for column
calibration (from left to right: conalbumin, 75 kDa; ovalbumin, 44 kDa; carbonic anhydrase, 29 kDa; ribonuclease A, 13 kDa and aprotinin, 6.5 kDa). DLS – 1 ml of puriﬁed
laforin was analysed in a Malvern Zetasizer Nano apparatus. Presented is the size distribution by number result.
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ten yield a rather homogeneous and relatively pure preparation
[20], which is, together with the high levels of protein production,
one of the advantages of producing recombinant protein in the
form of inclusion bodies [20].Laforin oligomerization state
Since laforin dimerization seems to be critical for its phospha-
tase activity [15], we have analyzed the oligomerization state of
the puriﬁed protein either by analytical size exclusion chromatog-
raphy (SEC) and dynamic light scattering (DLS). The SEC results
(Fig. 3 A) have shown that the protein is relatively homogeneous
in size, with a unique sharp and well deﬁned peak with an elution
volume corresponding to a 64 kDa protein, consistent with the di-
mer state of laforin (2  37 kDa). This result was later conﬁrmed by
DLS. The protein was analyzed in both the anion exchange elution
buffer (20 mM Tris, 0.4 M urea, 250 mM NaCl, pH 8.0) and in
50 mM Tris, 50 mM NaCl, pH 7.4, with similar results. The particles
detected had an hydrodynamic radius of 2.81 nm (Fig. 3 B) which,Table 2
Steady state kinetic parameters for laforin phosphatase activity.
Enzyme pNPP
kcat (s1) KM (mM) kcat/KM (s1 m
Laforin 0.56 ± 0.07 8.4 ± 0.7 0.07 ± 0.01
GST-pG laforin 1.1 ± 0.1 11.4 ± 3.0 0.10 ± 0.03
His-laforin 1.7 ± 0.2 33 ± 3 0.051 ± 0.004
Comparison with published data for tagged versions of laforin, taken from Ref. [16]. The
A B
Fig. 4. Laforin phosphatase activity characterization: Optimum pH (A) and inhibition b
substrate in 50 mM sodium acetate (pH 4.5–6.5) and 50 mM Tris–HCl (pH 7.0–8.5) (A) an
485 nm and emission set to 530 nm.according to the Malvern Zetasizer DLS software should corre-
spond to a globular protein with mass of 76 ± 16 kDa, which is
again consistent with the dimer state of laforin.Phosphatase activity characterization
The laforin phosphatase activity was characterized using both
p-nitrophenyl phosphate (pNPP) [21] and 3-O-methylﬂuoresceinyl
phosphate (OMFP), previously proposed as better substrate for
dual-speciﬁcity phosphatases than pNPP [16,22]. The kinetic
parameters (Table 2) have shown that the non-tagged version of
the protein puriﬁed in this study had similar properties when com-
pared to the previously published kinetic parameters for GST and
His tagged versions of laforin [16], conﬁrming the behavior of lafo-
rin as a dual-speciﬁcity phosphatase with OMFP as a better sub-
strate than pNPP. The pH proﬁle of laforin phosphatase activity
(Fig. 4 A) was again in agreement with the literature [2,16,17,23],
with the pH resulting in the maximal activity in the acidic range,
around pH 6.0. We have also looked for the capability of glycogen
to inhibit the phosphatase activity of laforin by including increas-OMFP
M1) kcat (s1) KM (mM) kcat/KM (s1 mM1)
7.6 ± 1.5 0.21 ± 0.05 36 ± 11
9.5 ± 2.0 0.26 ± 0.04 36 ± 13
6.5 ± 1.3 0.75 ± 0.29 8.7 ± 5.1
kinetic parameters were determined with 50 mM Tris/HCl buffer, pH 7.2 at 30 C.
y glycogen (B). Phosphatase activity was measured by ﬂuorescence using OMFP as
d in the presence of variable amounts of glycogen (B) at 30 C with excitation set to
Fig. 5. Starch binding assay. (1) laforin supernatant after centrifugation; (2)
supernatant after starch incubation; (3) starch washing supernatant; (4) superna-
tant after glycogen elution. All steps were done in duplicate. The gel was silver
stained.
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presented in (Fig. 4 B) show that laforin, in agreement with previ-
ously published results [16,17], is effectively inhibited by glycogen
with half the activity being obtained when laforin was incubated
with glycogen at concentrations around 50 lg/ml. We have also
tested the ability of laforin to bind starch by its CBM domain, as ob-
served for other members of CBM20 family. For that purpose we
have performed starch adsorption assays, as described under
Materials and methods section. The puriﬁed laforin (Fig. 5 1) was
incubated with starch and after 1 h the solution was centrifuged.
The SDS–PAGE analysis of supernatant revealed that most of the
protein was absent in this fraction. This is not due to precipitated
protein in the sample as we have centrifuged the protein sample
prior to the starch incubation. The subsequent washing steps of
the starch precipitate revealed no protein being washed (Fig. 5,
lane 3), and after glycogen elution step was performed it was clear
that it is effective in promoting the elution of laforin from starch
(Fig. 5, lane 4) as we could clearly identify the laforin band in the
SDS–PAGE. The cluster of bands between about 55 and 65 kDa seen
in all the SDS–PAGE lanes, are likely due to keratin contamination
in sample and/or in sample buffer. A stronger band might be ex-
pected at the glycogen elution step, based on the amount of protein
that was bound to the starch moiety, but the relatively faint band
resulting from the glycogen elution should be attributed to a stron-
ger binding of laforin towards starch than glycogen, as previously
reported [18].Conclusions
In this work, we have shown for the ﬁrst time that full-length
human laforin can also be produced in E. coli expression systems,
in high amounts and devoid of any fusion tags. The characteriza-
tion showed that we have produced a protein in dimeric state, with
kinetic parameters characteristic of dual-speciﬁcity phosphatases
and with a functional carbohydrate binding module. This protein
expression method might be used for the production of the high
amounts of protein needed for the determination of three-dimen-
sional structure of laforin, which will contribute to understand the
laforin molecular mechanism of action and ultimately contribute
to the development of therapies for Lafora disease.Acknowledgments
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